Aldo Bono

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Jorg R. Oddens, Maurizio Brausi, Richard Sylvester et al. · European Urology · 2012 · 497 citations

Urological Research, Urology, Maintenance Bacillus Calmette-guérin +8

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

Vinata B. Lokeshwar, Tomonori Habuchi, H. Barton Grossman et al. · Urology · 2005 · 426 citations

Urology, Urologic Cancer Epidemiology, Genitourinary Cancer +8

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Maurizio Brausi, Jorg R. Oddens, Richard Sylvester et al. · European Urology · 2013 · 359 citations

Urological Research, Urology, Genitourinary Cancer +7

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

Luigi Dogliotti, Giacomo Cartenì, Salvatore Siena et al. · European Urology · 2007 · 326 citations

Urology, Genitourinary Cancer, Medicine +6

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

Adrian P.M. van der Meijden, Richard Sylvester, W. Oosterlinck et al. · European Urology · 2003 · 288 citations

European Organisation, Urology, Maintenance Bacillus Calmette-guerin +8